Cargando...
Profile of pomalidomide and its potential in the treatment of myelofibrosis
Myelofibrosis, a Philadelphia-negative myeloproliferative neoplasm, is in a new treatment era after the discovery of the JAK2V617F mutation in 2005. JAK inhibitors boast improvements in disease-related symptoms, splenomegaly, and overall survival; however, treatment of myelofibrosis remains a challe...
Gardado en:
| Publicado en: | Ther Clin Risk Manag |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4397931/ https://ncbi.nlm.nih.gov/pubmed/25897239 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S69211 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|